CSIMarket
 

Curanex Pharmaceuticals Inc  (NASDAQ: CURX)

Curanex Pharmaceuticals Inc's

Competitiveness




 

CURX Sales vs. its Competitors Q2 2026







Revenue Growth Comparisons




Net Income Comparison




<<  CURX Stock Performance Comparisons


Curanex Pharmaceuticals Inc's Comment on Competition and Industry Peers


The inflammatory bowel disease (IBD) treatment market is highly competitive, with key companies including AbbVie, Janssen Biotech, Takeda Pharmaceutical, Pfizer, Merck, Novartis, and Boehringer Ingelheim. These firms focus on developing novel biologic therapies, expanding their product portfolios, and investing in research and development. Additional competitors with significant marketing and research capabilities include Regeneron/Sanofi, LEO Pharma, Eli Lilly, and Galderma. Competition also arises from academic institutions, government agencies, and various private and public research organizations.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Curanex Pharmaceuticals Inc



Sources: Curanex Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Curanex Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.